We are live on ! Find out more

Rhythm Pharmaceuticals

RYTM

Market cap $6.37B

92.57 USD

-0.50

0.54%

At close Updated Oct 30, 4:00 PM EDT

Pre-market

After hours

93.04

+0.47

0.51%

1 day

-0.54%

5 days

2.78%

1 month

-2.78%

3 months

-12.46%

6 months

13.78%

Year to date

-11.85%

1 year

-17.21%

5 years

665.04%

10 years

208.57%

About: Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Employees: 414

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 33.3%

Neutral 61.9%

Negative 4.8%

Zacks Investment Research

Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 3, 2026 to report its third quarter 2026 financial results and provide a corporate update.

Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

-- Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan's National Health Insurance drug price list -- -- IMCIVREE is the first approved therapy in Japan for patients living with acquired hypothalamic obesity --

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

Zacks Investment Research

Rhythm Pharmaceuticals (RYTM) Upgraded to Buy: Here's What You Should Know

Rhythm Pharmaceuticals (RYTM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Rhythm Pharmaceuticals (RYTM) Upgraded to Buy: Here's What You Should Know

Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm

NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) breached their fiduciary duties to shareholders.

Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity

BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that Health Canada has approved IMCIVREE® (setmelanotide) for the additional indication of weight management in adult and pediatric patients 4 years of age and older with acquired hypothalamic obesity (HO).

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting

-- Real-world data showed reductions in BMI with up to 18 months of setmelanotide therapy in 30 paediatric patients with acquired hypothalamic obesity (HO) in France – -- Phase 3 analyses demonstrated improvements across multiple cardiometabolic risk indices with setmelanotide in acquired HO -- BOSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced Rhythm and its collaborators will present three posters and three oral presentations relating to the company's work in rare melanocortin-4 receptor (MC4R) pathway diseases at the 64th Annual European Society for Paediatric Endocrinology (ESPE) Meeting taking place September 8-10 in Marseille, France.

Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting

Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Commercial launch in Japan expected by end of 2026, pending final pricing determination --

Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

The Motley Fool

Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can

Rhythm Pharmaceuticals develops medicines for rare forms of obesity. The company has little competition in its target market.

Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can

See News Rankings

Price charts implemented using Lightweight Charts™